Takeda settles patent suits relating to Actos
DEERFIELD, Ill., and OSAKA, Japan — Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.
Takeda and Takeda Pharmaceuticals North America granted Mylan, Watson and Ranbaxy licenses to enter the U.S. market with generic Actos on Aug. 17, 2012, subject to regulatory approval, or earlier under certain circumstances. Mylan, Watson and Ranbaxy are first-filers of abbreviated new drug applications with paragraph IV certifications for Actos, and it is anticipated that the Food and Drug Administration will grant these companies 180-day marketing exclusivity, Takeda said.
Takeda also granted Alphapharm, Sandoz, Aurobindo, Dr. Reddy, Wockhardt, the Synthon defendants, Teva and Torrent licenses to enter the U.S. market with generic Actos beginning 180 days after the first-filers, subject to regulatory approval. Takeda has granted Teva a license to market an authorized generic version of Actos in the United States beginning on Aug. 17, 2012, or earlier under certain circumstances.
Takeda is the inventor and developer of Actos, which was commercially launched in the United States in 1999 for the treatment of Type 2 diabetes and has been prescribed for more than 10 million patients to date.
No comments found
Adherence is boosted by face-to-face contact, study finds
WOONSOCKET, R.I. — Pharmacists at a retail pharmacy are the most influential healthcare "voice" in getting patients to take their medications as prescribed, followed by nurses talking with patients as they are discharged from a hospital, according to research sponsored by CVS Caremark.
The research, based on a review of more than 40 years of studies published in medical journals, found that both in-store pharmacists and hospital-based nurses are more effective than pharmacists communicating to a patient via the telephone or doctors instructing patients regarding prescriptions. The study looked at in-person, electronic, telephonic, fax and mail communications.
These findings are contained in two separate reviews of medical journal studies sponsored by CVS Caremark and carried out by a team of researchers from Harvard University, Brigham and Women’s Hospital and CVS Caremark.
This week, the American Journal of Managed Care published a review that focused on communications between pharmacists and nurses with their patients. The AJMC study built upon a review by the same researchers that focused on doctor and patient communications, which was published last May in the Journal of General Internal Medicine.
"There have been many studies on the subject of boosting adherence. We decided it was important to review the total body of work to determine which communication channel had the greatest impact," stated William Shrank of Brigham and Women’s Hospital and Harvard, and a lead author of the studies. Shrank said the researchers combed through more than 6,500 medical journal articles published between 1966 and Dec. 31, 2008, before reviewing 168 articles in full.
The study found that programs using mail, fax and brochure-type (nonpersonal) communications had relatively low impact on promoting patient adherence. A review of the use of electronic communications, such as videos and interactive technology, showed promise but those communications were determined to have medium impact on increasing adherence among patients.
The highest impact programs featured work by pharmacists talking to patients in a store, followed by nurses talking face-to-face with patients who were leaving a hospital, the researchers concluded. Face-to-face discussions between pharmacists and patients in a store were twice as effective in boosting adherence rates as programs where pharmacists talked with patients on the telephone, the researchers found.
"These findings offer payers, healthcare providers and policy-makers guidance about how to develop programs that improve patient adherence," added Troyen Brennan, EVP and chief medical officer of CVS Caremark and an author of both reviews. "We know that pharmacists and nurses are among the most trusted healthcare professionals. This study shows that trust translates into effective patient communications."
The study is a product of CVS Caremark’s previously announced three-year collaboration with Harvard University and Brigham and Women’s Hospital to research pharmacy claims data to better understand patient behavior, particularly around medication adherence.
This post is very interesting and I like to read it. It is providing such a helpful information about healthcare and boosting adherence. There are also great work done by AJMC who done study on this topic. Thank You. By the way I am Mayur Soni from Hammersmith, London. I am provider of Cabs and airport transfer service. www.dialacarlondon.com
I'd like to read this study. I see no mention of which healthcare professionals were studied,other than hospital discharging RNs and community pharmacists. As a Certified Diabetes Educator, I know that CDEs across the country spend a great deal of time instructing patients in the importance of taking their medications and taking them correctly. Can you please post a like so we can see who did the study, how many patients they studied, and what health professionals were evaluated?
Biogen acquires rights to neuro disease programs
WESTON, Mass. and ZURICH — In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.
Among other assets, the agreement gives Biogen the worldwide rights to three preclinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system targets: alpha-synuclein, tau and TDP-43.
“These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis,” both companies said in a joint statement. Biogen revealed it will make an initial payment of $32.5 million for the rights to the three programs in pre-clinical development, and up to $395 million in contingent payments. Under terms of the deal, Biogen will be responsible for the development of the preclinical candidates and the commercialization of all products.
Neurimmune will pursue additional scientific activities with respect to the lead candidates as well as the discovery of back-up candidates, utilizing its Reverse Translational Medicine technology platform.
Neurimmune also retains the right to use its platform for creating therapeutic antibody products outside the scope of its agreement with Biogen, according to the agreement.
No comments found